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Abstract. Benzotriazole is a very useful synthetic auxiliary with versatile applications in organic chemis-
try. We have used benzotriazole in the synthesis of various heterocyclic compounds (benzoxazine, 
quinazoline, triazinetrione, hydantoin, oxadiazine and diazepane derivatives), amino acid derivatives, car-
bamates, ureas, semicarbazides, carbazides, sulfonylureas, sulfonylcarbazides, hydantoic acids, non-
steroidal antiinflammatory drug (NSAID) and primaquine derivatives, polymer-drug and thiomer-drug 
conjugates. The results have been published in more than 30 papers and here we give an overview of all 
syntheses. (doi: 10.5562/cca2124) 
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INTRODUCTION 
Benzotriazole is an aromatic five-membered hetero-
cyclic compound condensed with benzene. It is clasified 
as an azole, together with pyrazole, imidazole, 1,2,3- 
and 1,2,4-triazole, tetrazole, indazole and benzimid-
azole. Many years ago, H. A. Staab and collaborators 
systematically investigated N-substituted azoles and 
found out their high reactivity.1,2 Staab considered imid-
azole as the most convenient azole, and 1,1'-carbonyl-
diimidazole (CDI) has found its use in numerous syn-
theses. Contrary to most other azoles, benzotriazole 
reacts with phosgene in a molar ratio 1:1, yielding  
1-benzotriazole carboxylic acid choride (1-benzotriazo-
lecarbonyl chloride, BtcCl, 1).3 Phosgene used in origi-
nal synthetic procedure was later on replaced with tri-
phosgene (Scheme 1).4 Today, chloride 1 is a commer-
cially available compound. 
A. R. Katritzky gave enormous contribution to develop-
ment of benzotriazole chemistry. Since 1985, he has 
published more than 300 papers and several reviews 
dealing with benzotriazole.5–11 He defined benzotriazole 
as a compound which fulfils all demands of an ideal 
synthetic auxiliary: it is inexpensive, stable, it can be 
introduced readily at the beginning of the reaction se-
quence, it is stable during various synthetic operations, 
it exerts an activating influence on the other parts of the 
molecule, it is easy to remove and can be recovered and 
used again.12 
Our group started with benzotriazole chemistry in 
1977 and the results have been published in more than 
30 papers. In this review, all the versatile reactions in 
which we have used benzotriazole are presented and 
shortly discussed. 
 
REACTIONS OF BtcCl WITH AMINO  
COMPOUNDS AND ALCOHOLS 
Firstly, we investigated the reaction of BtcCl (1) with 
amines, hydrazines and alcohols. Products of the reac-
tions, 1-carbamoylbenzotriazoles 2, reactive hydrazides 
8 or carbamates 11 reacted readily with amino com-
pounds when appropriate reaction conditions were ap-
plied (Scheme 2). More basic amines reacted at room 
temperature, while weaker nucleophiles, such as aniline, 
at higher temperature and upon prolonged reaction time. 
 
Scheme 1. Synthesis of 1-benzotriazole carboxylic acid 
chloride (BtcCl, 1). 
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A number of symmetrical and asymmetrical ureas 3, 
sulfonylureas 4, semicarbazides 5 and 6, carbazides 9, 
sulfonylcarbazides 10 and carbamates 12 were pre-
pared.3,13–16 Semicarbazide 6 reacted with another mole 
of chloride 1, affording 1-(1-benzotriazolecarbonyl)-4-
alkyl/arylsemicarbazides 7. The reactions of BtcCl with 
amino compounds could be performed as one-pot reac-
tions as well. In the first step chloride 1 reacted with one 
mole of amine (hydrazine) and compounds 2 or 8 were 
prepared. Upon addition of the second mole of the same 
or different amine (hydrazine), symmetrical or asym-
metrical ureas 3 and carbazides 9 were obtained. 
The analogous reactions were later on applied in 
the synthesis of non-steroidal antiinflammatory drugs 
(NSAID) semicarbazides, hydroxysemicarbazides and 
carbazides (discussed in the separate paragraph). 
 
SYNTHESIS OF BENZOXAZINE, QUINAZOLINE, 
TRIAZINE DERIVATIVES AND HYDROXYUREAS 
Synthesis of benzoxazine derivatives 15 and 16 and 
quinazoline derivative 19 started with reaction of chlo-
ride 1 with antranilic acid, through intermediates 13 and 
14 (Scheme 3).17 
Chloride 1 reacted with N-benzylhydroxylamine 
and gave 1-(N-benzyloxycarbamoyl)benzotriazole (2a). 
Benzyl group was removed by hydrogenolysis and the 
obtained product 2b was used for the synthesis of hy-
droxyurea derivatives 20. After heating, compound 2a 
dissociated into N-benzyloxycyanate (21), which trimer-
ized to product 22. Hydrogenolysis of 22 gave trihydroxy-
triazinetrione 23 in quantitative yields.4 
 
SYNTHESIS OF AMINO ACID DERIVATIVES: 
HYDANTOINS, UREIDOAMIDES, OXADIAZINES 
The reaction of chloride 1 with amino acids enabled the 
use of benzotriazole both in peptide chemistry and in 
synthesis of hydantoins 28 and ureidoamides 29 and 
30.18–21 The crucial intermediers N-(1-benzotriazole-
carbonyl)-amino acids 24 were prepared from chloride 1 
and two moles of amino acids and then transformed to the 
corresponding chlorides 25, esters 26 and amides 27.22  
N-(1-benzotriazolecarbonyl)-amino acid amides 27 in 
alkaline medium or upon heating quantitatively cyclized to 
3,5-disubstituted hydantoins (imidazolidine-2,4-diones) 
28. The substituent at position 3 depended on the used 
amine, while substituent at position 5 originated from the 
amino acid. Hydrolysis of amides 27 under acidic condi-
tions gave amino acid amides 32.23 Benzotriazole moiety 
in compounds 27 was readily replaced with amines or 
hydroxylamines affording ureidoamides 29 and hy-
droxyureidoamides 30.24-26 Ureidoamides 31 were pre-
pared directly from chlorides 25 with excess of 2-
aminoethanol, 3-aminopropanol and 5-aminopentanol.27 
On the other hand, amidation of chlorides 25 with  
N-phenylhydroxylamine gave hydroxamic acids 33, 
which readily cyclized to oxadiazines 34 (Scheme 4).28  
 
Scheme 2. Reactions of BtcCl with amino compounds and alcohols. 
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Scheme 3. Synthesis of benzoxazine, quinazoline, triazine derivatives and hydroxyureas. 
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Scheme 4. Synthesis of amino acid derivatives: hydantoins, ureidoamides and oxadiazines. 
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SYNTHESIS OF OLYGOPEPTIDES 
N-(1-benzotriazolecarbonyl)-amino acids 24 were the 
starting compounds in the synthesis of amino acid, di- 
and tripeptide derivatives. Btc group played a triple role 
in the peptide synthesis: N-protecting, N-activating and 
both N-protecting/C-activating role.  
Removing of the Btc N-protecting group from  
amides 27 was performed in mild conditions, with trifluo-
roacetic acid or diluted HCl solution at room temperature, 
as it is already mentioned in the previous paragraph. 
N-activating role of Btc group is outlined in 
Scheme V, the line leading to compounds 38.23,29 This 
method of peptide bond formation is similar to methods 
described by Goldschmidt30 and Gante,31,32 which inclu-
de reaction of N-protected amino acid with -iso-
cyanoalkane acids. In our synthesis, unstable and toxic 
isocyano derivatives were replaced with N-Btc-amino 
acid esters 26 which upon heating dissociated to iso-
cyanates and reacted with N-protected amino acids, 
yielding peptide derivatives 38 in 60 % average yields. 
Double role of Btc group as N-protecting/C-acti-
vating was observed in direct preparation of amino acid 
esters 42, amides 32, hydroxamic acids 43 and di- and 
tripeptides 40 from starting compounds 24 and corres-
ponding alcohols, amines, hydroxylamines and amino 
acids or dipeptides (Scheme 5).23,25,29,33 The reactions 
proceeded through N-carboxy amino acids (NCA) inter-
mediates 39.34 
 
SYNTHESIS OF NSAID DERIVATIVES 
NSAIDs and syntheses of their derivatives were heavily 
explored. NSAIDs contain carboxylic acid moiety, 
which makes them suitable for further derivatization. 
The reactions of NSAIDs with chloride 1 gave inter-
mediate mixed anhydrides, which decarboxylated to 
NSAID benzotriazolides 44, stabile solids with acti-
vated carboxylic moiety.35 Compounds 44 readily re-
acted with a number of nucleophiles (alcohols, amines, 
hydroxylamines, hydrazine and polymers) under mild 
conditions yielding esters,35–37 amides 46,36,38–41 hydrox-
amic acid 47,42,43 hydrazides 48,44 hydroxyamides 49,45 
and polymer-NSAID and thiomer-NSAID conjugates 
5035,37,46–48 (for more information see the last para-
graph). Ureidoamides 31 with two hydroxyl groups, 
reacted with two moles of NSAID-Bt 44 and gave esters 
51 (Scheme 6).49 
NSAID hydrazides 48 were the starting com-
pounds for a number of further reactions. First, they 
reacted with 1-(N-alkyl/arylcarbamoyl)benzotriazoles 2, 
yielding 1-acyl-4-substituted semicarbazides 52.44 If  
the reaction was performed with 1-(N-benzyloxycarba-
moyl)benzotriazole 2a, benzyloxysemicarbazides 53 
Scheme 5. Benzotriazolecarbonyl group as N-protecting, N-activating and both N-protecting/C-activating group. 
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were obtained, which after catalytic hydrogenation gave 
1-acyl-4-hydroxysemicarbazides 54.44 1-Acyl-5-substi-
tuted carbazides 55 were the products of the reaction of 
NSAID hydrazides 48 and 1-(1-benzotriazolecarbonyl)-
4-benzyloxysemicarbazide 7a.44 Their hydrogenation 
resulted in 1-acyl-5-hydroxycarbamoylcarbazides 56. 44 
3-Hydroxypropanamides 49 were the starting mate-
rials for the reaction with p-chlorophenyl (methoxy-L-
alanyl)phosphochloridate and the corresponding phos-
phoramidates 57 were obtained.45 
SYNTHESIS OF PRIMAQUINE DERIVATIVES 
Primaquine (PQ) is a well-known antimalarial drug and 
an interesting molecule for the derivatization in the 
search for potential pharmacological agents.50,51 
Synthetic pathways towards PQ derivatives using 
benzotriazole as a synthetic auxiliary could be divided 
into two major routes. The first was the one in which 
PQ reacted with BtcCl yielding PQ benzotriazolide 58,52 
which was the starting material for the preparation  
Scheme 6. Synthesis of NSAID derivatives. 
NSAID = Ibu, Dic, Ind, Fen, Ket, MeKet
NSAID OH
O
BtcCl
NSAID N
O
ROH RNH2
N
N
NSAID OR
O
NSAID NHR
O
R1NHOR2
NSAID N
O
OR2
R1
H2NNH2
NSAID
O
N
H
NH2
NSAID N
H
O
OH
H2N(CH2)3OH
OH N
H
N
H
H
N OH
O R
O
O N
H
N
H
H
N O
O R
O
NSAID
O
NSAID
O
polymer
BtcNHR
BtcNHOBn
NSAID
O
N
H
H
N
H
N
R
O
NSAID
O
N
H
H
N
H
N
O
O
Bn
H2/Pd/C
NSAID
O
N
H
H
N
H
N
OH
O
N
H
P
O
Cl
O
Cl O
O
NSAID N
H
O
O
P
O
Cl
O
NH
O
O
Btc
H
N
N
H
N
H
O
Bn
O
NSAID
O
N
H
H
N
H
N
N
HO
N
H
O
Bn
O
NSAID
O
N
H
H
N
H
N
N
HO
N
H
OH
O
H2/Pd/C
polymer-drug
conjugates
31
44
45
46
47
48
49
5051
52
53
54
55
56
57
2
2a
7a
n
n
n
n
 
Figure 1. Structures of the drugs used in preparation of polymer-drug conjugates. 
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of PQ ureas 59,52 carbamates 6053 and polymer-PQ 
conjugates 61.54 PQ ureas were obtained by aminolysis 
of benzotriazolide 58 with various amines, hydroxy-
amines and ethylenediamine,52,53 whereas PQ carba-
mates were prepared by the analogous reactions with 
alcohols.53 Diazepane derivative 62 was obtained by 
cyclization of PQ benzotriazolide in alkaline medium.53 
The reaction of PQ benzotriazolide with two  
polymers, polyα,β-(N-2-hydroxyethyl-DL-aspartamide) 
(PHEA) and polyα,β-(N-3-hydroxypropyl-DL-aspart-
amide) (PHPA), yielded two polymer-PQ conjugates 
61.54 For more details on polymer-drug conjugates, see 
the next paragraph. 
In the second pathway, PQ reacted as an primary 
amine with benzotriazole containing precursors, NSAID 
benzotriazolides 44 and 1-(1-benzotriazolecarbonyl)-4-
cycloalkyl/aryl semicarbazides 7; the former yielding 
NSAID-PQ twin drugs 63,55 and the latter PQ semi-
carbazides 64.56 Synthesis of primaquine derivatives is 
outlined in Scheme 7. 
 
SYNTHESIS OF POLYMER-DRUG CONJUGATES 
Benzotriazole was also applied in preparation of poly-
mer-drug and thiomer-drug conjugates, polymeric pro-
drugs with drugs covalently bind to the polymeric car-
riers (Scheme 8). Binding of drugs from various thera-
peutic groups to polymers of polyaspartamide type by 
benzotriazolide method was performed and described in 
several papers. The following drugs were used: NSAIDs 
(ketoprofen, Ket, indomethacin, Ind, fenoprofen, Fen, 
diclofenac, Dic, ibuprofen, Ibu),35,37,46–48 antihyper-
lipemic (gemfibrozil, Gem),48,57,58 estrogens (estradiol 
benzoate, EB, estradiol valerate, EV),59,60 uricosuric 
(probenecid, Pro)36 and antimalarian drug primaquine, 
PQ.56 Structures of the drugs used in preparation of 
polymer-drug conjugates are presented in Figure 1. 
Polymers of polyaspartamide type rich in hydroxyl 
and amino functionalities or thiomers bearing additional 
SH groups were prepared by aminolysis of poly-DL-
(2,5-dioxo-1,3-pyrrolidinediyl) (PSI) with 2-hydroxy- 
ethylamine, 3-hydroxypropylamine, ethylendiamine, 
cysteamine, methyl-(2-amino-4-mercapto)-butyrate or 
their combination, while PSI was prepared by thermal 
polycondensation of L-aspartic acid. The following 
polymers and copolymers were used in polymer-drug 
conjugate preparation: poly,-(N-2-hydroxyethyl-DL-
aspartamide) (PHEA), polyα,β-(N-3-hydroxypropyl- 
DL-aspartamide) (PHPA), polyα,β-(N-2-aminoethyl- 
DL-aspartamide)-polyα,β-(N-2-hydroxyethyl-DL-aspart- 
amide) copolymer (PAHA), poly[α,β-(N-2-hydroxy- 
ethyl-DL-aspartamide ) ]-poly[ α,β-( N-2-thioethyl-DL-aspart- 
amide)] (PHTA), poly[α,β-(N-2-aminoethyl-DL-aspart- 
amide) ]-poly[ α,β-( N-2-hydroxyethyl-DL-aspartamide ) ]-
polyα,β-(N-3-mercapto-1-methoxycarbonyl-propyl-D,L-
aspartamide) copolymer (PAHMA) or poly[α,β-(N-2-
aminoethyl - DL - aspartamide ) ] - poly[ α,β - ( N - 2 - hydroxy-
ethyl-DL-aspartamide ) ]-poly[ α,β-( N-2-thioethyl-DL-aspart-
amide)] copolymer (PAHTA).  
In the first step, carboxyl or hydroxyl group of the 
drugs reacted with chloride 1, affording benzotriazo-
lides 44 or active carbamates 65, which readily reacted 
with hydroxyl or amino groups of polymers and gave 
the polymer-drug conjugates 50, 61 or 66.35,37,46–48,56,57–60 
With amino acids (glycine and β-alanine) or ethylene-
diamine derivatives 67 and 70 with additional functional 
group useful for further derivatization or binding to 
polymers were obtained and used in preparation of the 
 
Scheme 7. Synthesis of primaquine derivatives. 
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conjugates with a spacer between polymer and drug.46,58 
More than twenty polymer-drug conjugates were pre-
pared, which differed in the polymer type, average mo-
lecular mass, bound drug, type of polymer-drug bond 
(ester, amide or carbamate), type of spacer and drug-
loading. Such macromolecular conjugates may offer 
many advantages compared to other drug delivery sys-
tems such as increased drug solubility, prolonged drug 
release, increased stability. It is also possible to accumu-
late drug at the site of the pathological process and to 
minimize its toxicity. 
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Scheme 8. Synthesis of polymer-drug conjugates. 
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